Immunoprecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

IPA reports record revenue and seeks funding for future growth

IPA's Q2 '23 earnings call highlighted record revenue, strategic program consolidation, and advancements in R&D. While facing cash needs and the need to raise funds, the company remains optimistic about future partnerships and the potential for data management transactions.

Immunoprecise Antibodies reports strong revenue growth and strategic collaborations

Immunoprecise Antibodies Ltd (IPA) had a strong quarter with revenue growth and valuable research collaborations, positioning the company for future success despite operational challenges.
IPA's focus on innovation, disruptive AI-driven collaborations, and strategic changes to boost profits highlight a positive growth trajectory and commitment to addressing unmet medical needs.

Immunoprecise Antibodies reports record revenue, eyes strategic partnerships for growth

IPA's Q4 '23 earnings call reflects strong revenue growth, strategic collaborations, and a focus on operational efficiency, positioning the company for future success.
While facing financial challenges and the need for fundraising, IPA's technological strengths, partnerships, and market opportunities offer avenues for growth and innovation.
The company's performance highlights resilience in the biotech sector, with a clear roadmap for enhancing shareholder value and advancing R&D capabilities.

Immunoprecise Antibodies Ltd posts strong Q1 earnings, eyes U.S. investors

Immunoprecise Antibodies Ltd (IPA) reports robust Q1 2024 earnings, marked by significant revenue growth and improved financial metrics. The company showcases strengths in strategic leadership, cost management, and expansion initiatives, while facing challenges in managing net losses and financial transparency. IPA has opportunities to capitalize on its strengths and attract more investors through the SEC shelf offering.

Immunoprecise Antibodies Ltd reports record Q2 revenue growth

IPA's Q2 2024 earnings call showcased robust revenue growth, operational improvements, and strategic initiatives driving the company forward.
While facing industry challenges, IPA's focus on client trust, cost management, and innovation positions it well for future success.
The company's commitment to governance, shareholder engagement, and exploring new revenue streams highlights a proactive approach to growth.

Immunoprecise Antibodies Ltd (IPA) reports strong Q3 performance and strategic investments

Immunoprecise Antibodies Ltd (IPA) delivered a robust performance in Q3 2024, marked by revenue growth, profit margin improvements, and strategic investments in BioStrand. While facing a net loss, IPA maintains a healthy cash balance and focuses on R&D efficiency. The company's strengths in innovation and customer commitment position it well for future growth, with opportunities to leverage its momentum for market expansion.

Immunoprecise Antibodies (IPA) reports 19% revenue growth in 2024

Immunoprecise Antibodies Ltd (IPA) delivered strong financial performance in fiscal year 2024, with revenue growth, reduced operating expenses, and successful product launches. Strategic collaborations and industry recognition highlight IPA's competitive strengths. Addressing commercialization challenges and seizing growth opportunities will be key focus areas for future success.

Immunoprecise Antibodies reports revenue growth and strategic advancements in Q1

IPA's Q1 2025 performance reflects revenue growth driven by VHH antibody programs and strategic inventory management.
The company's strengths lie in its AI-driven platform, strong pipeline, and balanced revenue generation models.
Challenges include maintaining financial consistency, effective inventory management, and staying competitive in the evolving market.
Opportunities for IPA include sustained growth through fee-for-service work, revenue diversification via licensing, and leadership in biotechnology innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA's latest advancements in AI-driven design, biologics innovation, and strategic technological developments. Highlights of TECHDAY: Prese.

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces its significant contribution to a groundbreaking study. The research, led by top scientists at the Mayo Clinic, was initially published in bioRxiv and subsequently peer-reviewed and published in the prestigious journal Autophagy. Titled "Development and Characterization of Phospho-Ubiquitin Antibodies to Monitor.

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA's AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Seaport District Hotel, Boston, Massachusetts, November 12-14, 2024. AI Driven Drug Discovery Summit Date:.

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

Marcus & Millichap

LOS ANGELES--(BUSINESS WIRE)-- #apartmentbrokers--Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District.

Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today celebrates the recent Nobel Prize in Chemistry awarded to David Baker of the University of Washington, Seattle, WA, USA, "for computational protein design," and jointly to Demis Hassabis and John M. Jumper of Google DeepMind, London, UK, "for protein structure prediction." This accolade highlights the vital role of.

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

VICTORIA, British Columbia & ZHUHAI, China--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, and Biotheus Inc. (Biotheus), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, jointly announce that the two parties have entered into a Material Transfer and Evaluation Agreement (MTEA) pertaining to a Talem therapeutic antibo.

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using IPA's proprietary B Cell Select® platform for the clinical-stage company, OncoResponse Inc. This achievement underscores IPA's leadersh.

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q1 2025 Earnings Conference Call September 16, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants Swayampakula Ramakanth - H.C.

ImmunoPrecise Antibodies Ltd. (IPA) Q1 2025 Earnings Call Transcript

ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09.

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Misses Revenue Estimates

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for the first quarter of its 2025 fiscal year (“FY25”), which ended July 31, 2024. All numbers are expressed in Canadian dollars, unless otherwise noted. "Our commitment to end-to-end in silico engineering of antibodies for challenging targets has delivered exceptional.

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2025, on Monday, September 16, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecis.

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), is pleased to announce that it will be attending H.C. Wainwright's 26th Annual Global Investment Conference (the "Global Investment Conference"). The Company's management team invites shareholders and all interested parties to attend. Admission to the Global Investment Conference is free to qualified investors. The Global Investment Conference will be held in-person at the Lotte Ne.

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutics company, announced today that the Company received written notification (the "Notification Letter") from the Nasdaq Global Market LLC ("Nasdaq") on August 19, 2024, indicating that the Company is not in compliance with the minimum bid price requirement set forth in the Nasdaq Rule 5450(a)(1) based on the closing bid price of the Company's common shares.

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutics company, today announced a groundbreaking achievement: the ability to engineer antibodies entirely through computer simulations using LENSai. This marks a significant milestone for the biotechnology industry. Additionally, the antibodies produced by IPA are highly specific to a challenging oncology target located within the Tumor Microenvironment (TME).

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q4 2024 Earnings Conference Call July 29, 2024 10:30 AM ET Company Participants Jennifer Bath - Chief Executive Officer Kristin Taylor - Chief Financial Officer Conference Call Participants Will McHale - Ingalls & Snyder Swayampakula Ramakanth - H.C.

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2024 Earnings Call Transcript

ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.10.

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (“IPA”, “Company”, “we” or “us”) (NASDAQ: IPA), an artificial intelligence (AI)-driven biotherapeutic research and technology company, today announced its financial results for the fiscal year ended April 30, 2024. All numbers are expressed in Canadian dollars unless otherwise noted. “IPA has achieved significant milestones this fiscal year,” said Dr. Jennifer Bath, CEO and President of IPA. "We are proud to report our f.

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) today announces the rescheduling of its full year fiscal 2024 financial results and business highlights release. Originally set for July 25, 2024, the new release date is Monday, July 29, 2024, and will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary valuation calculations on goodwi.

ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”), under which the Company agreed to sell and issue to Yorkville $3.0 million aggregate principal amount of convertible.

ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, will announce its full year fiscal 2024 financial results and business highlights on Thursday, July 25, 2024, and will hold an earnings call at 10:30 am Eastern Time the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on IPA's Investor Relations website at.

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce the appointment of Kristin Taylor as Chief Financial Officer, effective immediately. Ms. Taylor has been serving as Interim CFO since September 19th, 2023, and now transitions into the role on a permanent basis. Ms. Taylor is a seasoned financial executive with extensive experience in both early-sta.

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating with PGxAI to leverage BioStrand's patented Foundation AI Model, LENSai. This collaboration advances the precision medicine field of pharmacogenomics and supports LENSai Application Programming Interface (“API”) commercial rollout through expanding LENSai fe.

IPA's Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems. This recognition highlights BioStrand's groundbreaking work in biotherapeutic research, which has made a significant impact and set a new standard for innovation in the in.

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces the commercial release of LENSai API, hereafter referred to as the ‘software', by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately. More details on this new offering will be unveiled today at 2:00 pm ET, with an additional presentation, live.

BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that its Belgian subsidiary, BioStrand, is leveraging their patented Foundation AI Model, LENSai, by applying advanced Large Language Models (LLM) to capture real world data from Electronic Health Records (EHR). LENSai significantly enhances the analysis and integration of EHR da.

News for Immunoprecise Antibodies Ltd Stock (IPA)